Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long-term results of a prospective phase II clinical trial

Ítems similars

• Fludarabine with Myeloablative Timed-Sequential Busulfan in Older Patients: Results of a Randomized Phase II Clinical Trial
  per: Popat, Uday R., et al.
  Publicat: (2018)
• PHASE II TRIAL OF GVHD PROPHYLAXIS WITH POST-TRANSPLANTATION CYCLOPHOSPHAMIDE FOLLOWING REDUCED-INTENSITY BUSULFAN/FLUDARABINE (BU/FLU) CONDITIONING FOR HEMATOLOGICAL MALIGNANCIES
  per: Alousi, Amin M., et al.
  Publicat: (2015)
• Clofarabine±Fludarabine with Once Daily IV Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and MDS
  per: Andersson, Borje S., et al.
  Publicat: (2010)
• Reduced intensity vs. myeloablative conditioning with fludarabine and PK-guided busulfan in allogeneic stem cell transplantation for patients with AML/MDS
  per: Alatrash, Gheath, et al.
  Publicat: (2018)
• Myeloablative reduced-toxicity IV busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life
  per: Alatrash, Gheath, et al.
  Publicat: (2011)